person · Reporting owner

Montgomery Alan Bruce

Disclosed activity across 4 companies

Tapewire entity: 17295
SEC CIK: 0001313936

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Xencor IncXNCR · Entity 4487	Director	June 16, 2026	July 08, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Xencor Inc

Report date June 16, 2026 · Filed July 08, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	25,849	Reported balance After 2026-06-16 transaction · row 1 1 source row Row 1 · 2026-06-16 · Grant · Acquired 10,302 · Balance 25,849 F1: Represents restricted stock units that shall fully vest on the first anniversary of the date of grant.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.20 · Expires 2036-06-15	Direct	20,604	Reported balance After 2026-06-16 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-16 · Grant · Acquired 20,604 · Balance 20,604 F2: The shares subject to the option will vest in equal monthly installments over one year beginning on the one-month anniversary of June 16, 2026, such that the total number of shares will be fully vested on June 16, 2027.

Filing footnotes · ownership attribution and instrument terms

F1: Represents restricted stock units that shall fully vest on the first anniversary of the date of grant.

F2: The shares subject to the option will vest in equal monthly installments over one year beginning on the one-month anniversary of June 16, 2026, such that the total number of shares will be fully vested on June 16, 2027.

Past disclosures · reporting ended (3)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

ALDER BIOPHARMACEUTICALS INC

Report date October 22, 2019 · Filed October 24, 2019

Section 16 reporting ended · disclosed 2019-10-24. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2019-10-22 transaction · row 1 1 source row Row 1 · 2019-10-22 · Other · Disposed 9,628 · Balance 0 F1: On September 16, 2019, the Reporting Person entered into a Tender and Support (the "Support Agreement") with H. Lundbeck A/S ("Lundbeck"), Lundbeck LLC, Violet Acquisition Corp., a wholly owned subsidiary of Lundbeck ("Purchaser") and certain other securityholders of Issuer, pursuant to which the Reporting Person agreed to tender all shares of the Issuer's Common Stock, Class A-1 Convertible Preferred Stock or shares of Common Stock underlying stock options, as the case may be, held by Reporting Person to Purchaser (the "Tender Offer"). On October 22, 2019, Purchaser accepted the Tender Offer. F2: The Reporting Person will also receive one non-transferable contingent value right for each share held, which will entitle them to receive up to an additional $2.00 per share upon achievement of a milestone.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.96 · Expires 2021-05-09	Direct	Reported balance After 2019-10-22 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2019-10-22 · Disposition to issuer · Disposed 12,727 · Balance 0 F3: On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Lundbeck, Lundbeck LLC and Purchaser. On October 22, 2019 (the "Effective Time"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck. F4: The shares subject to this option shall vest at a rate of twenty-five percent of the total number of shares on the one-year anniversary of October 25, 2010 (the "2010 Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the 2010 Vesting Commencement Date thereafter for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the 2010 Vesting Commencement Date. The shares subject to this option are fully vested as of the date hereof. F5: The shares subject to this option, whether or not vested, were cancelled and converted into the right to receive both (i) a cash payment equal to (A) the excess, if any of (x) $18.00 over (y) the Exercise Price per share listed in Column 2 of Table II of this Form 4, multiplied by (B) the total number of shares listed in Column 5 of Table II of this Form 4, and (ii) one non-transferable contingent value right for each share subject to this option, which represents the contractual right to receive up to an additional $2.00 per share upon achievement of a milestone.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.47 · Expires 2023-03-12	Direct	Reported balance After 2019-10-22 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2019-10-22 · Disposition to issuer · Disposed 6,363 · Balance 0 F3: On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Lundbeck, Lundbeck LLC and Purchaser. On October 22, 2019 (the "Effective Time"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck. F5: The shares subject to this option, whether or not vested, were cancelled and converted into the right to receive both (i) a cash payment equal to (A) the excess, if any of (x) $18.00 over (y) the Exercise Price per share listed in Column 2 of Table II of this Form 4, multiplied by (B) the total number of shares listed in Column 5 of Table II of this Form 4, and (ii) one non-transferable contingent value right for each share subject to this option, which represents the contractual right to receive up to an additional $2.00 per share upon achievement of a milestone. F6: The shares subject to this option shall vest at a rate of twenty-five percent of the total number of shares on the one-year anniversary of January 1, 2012 (the "2012 Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the 2012 Vesting Commencement Date thereafter for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the 2012 Vesting Commencement Date. The shares subject to this option are fully vested as of the date hereof.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.47 · Expires 2023-03-12	Direct	Reported balance After 2019-10-22 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2019-10-22 · Disposition to issuer · Disposed 6,363 · Balance 0 F3: On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Lundbeck, Lundbeck LLC and Purchaser. On October 22, 2019 (the "Effective Time"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck. F5: The shares subject to this option, whether or not vested, were cancelled and converted into the right to receive both (i) a cash payment equal to (A) the excess, if any of (x) $18.00 over (y) the Exercise Price per share listed in Column 2 of Table II of this Form 4, multiplied by (B) the total number of shares listed in Column 5 of Table II of this Form 4, and (ii) one non-transferable contingent value right for each share subject to this option, which represents the contractual right to receive up to an additional $2.00 per share upon achievement of a milestone. F7: The shares subject to this option shall vest at a rate of twenty-five percent of the total number of shares on the one-year anniversary of January 1, 2013 (the "2013 Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the 2013 Vesting Commencement Date thereafter for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the 2013 Vesting Commencement Date. The shares subject to this option are fully vested as of the date hereof.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.33 · Expires 2024-01-08	Direct	Reported balance After 2019-10-22 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2019-10-22 · Disposition to issuer · Disposed 6,363 · Balance 0 F3: On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Lundbeck, Lundbeck LLC and Purchaser. On October 22, 2019 (the "Effective Time"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck. F5: The shares subject to this option, whether or not vested, were cancelled and converted into the right to receive both (i) a cash payment equal to (A) the excess, if any of (x) $18.00 over (y) the Exercise Price per share listed in Column 2 of Table II of this Form 4, multiplied by (B) the total number of shares listed in Column 5 of Table II of this Form 4, and (ii) one non-transferable contingent value right for each share subject to this option, which represents the contractual right to receive up to an additional $2.00 per share upon achievement of a milestone. F8: The shares subject to this option shall vest at a rate of twenty-five percent of the total number of shares on the one-year anniversary of January 1, 2014 (the "2014 Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the 2014 Vesting Commencement Date thereafter for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the 2014 Vesting Commencement Date. The shares subject to this option are fully vested as of the date hereof.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $39.66 · Expires 2025-05-18	Direct	Reported balance After 2019-10-22 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2019-10-22 · Disposition to issuer · Disposed 6,350 · Balance 0 F3: On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Lundbeck, Lundbeck LLC and Purchaser. On October 22, 2019 (the "Effective Time"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck. F9: The shares subject to this option shall fully vest and become exercisable on the date of the 2016 Annual Meeting of the Stockholders of the Issuer, so long as the Reporting Person provides continuous service to the Issuer through such date. The shares subject to this option are fully vested as of the date hereof. F10: The shares subject to this option, whether vested or not, were cancelled at the Effective Time without any consideration payable therefor.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.26 · Expires 2026-05-25	Direct	Reported balance After 2019-10-22 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2019-10-22 · Disposition to issuer · Disposed 15,000 · Balance 0 F3: On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Lundbeck, Lundbeck LLC and Purchaser. On October 22, 2019 (the "Effective Time"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck. F10: The shares subject to this option, whether vested or not, were cancelled at the Effective Time without any consideration payable therefor. F11: The shares subject to this option shall fully vest and become exercisable on the date of the 2017 Annual Meeting of the Stockholders of the Issuer, so long as the Reporting Person provides continuous service to the Issuer through such date. The shares subject to this option are fully vested as of the date hereof.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.90 · Expires 2027-05-23	Direct	Reported balance After 2019-10-22 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2019-10-22 · Disposition to issuer · Disposed 15,000 · Balance 0 F3: On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Lundbeck, Lundbeck LLC and Purchaser. On October 22, 2019 (the "Effective Time"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck. F5: The shares subject to this option, whether or not vested, were cancelled and converted into the right to receive both (i) a cash payment equal to (A) the excess, if any of (x) $18.00 over (y) the Exercise Price per share listed in Column 2 of Table II of this Form 4, multiplied by (B) the total number of shares listed in Column 5 of Table II of this Form 4, and (ii) one non-transferable contingent value right for each share subject to this option, which represents the contractual right to receive up to an additional $2.00 per share upon achievement of a milestone. F12: The shares subject to this option shall fully vest and become exercisable on the date of the 2018 Annual Meeting of the Stockholders of the Issuer, so long as the Reporting Person provides continuous service to the Issuer through such date. The shares subject to this option are fully vested as of the date hereof.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.50 · Expires 2028-05-22	Direct	Reported balance After 2019-10-22 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2019-10-22 · Disposition to issuer · Disposed 15,000 · Balance 0 F3: On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Lundbeck, Lundbeck LLC and Purchaser. On October 22, 2019 (the "Effective Time"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck. F5: The shares subject to this option, whether or not vested, were cancelled and converted into the right to receive both (i) a cash payment equal to (A) the excess, if any of (x) $18.00 over (y) the Exercise Price per share listed in Column 2 of Table II of this Form 4, multiplied by (B) the total number of shares listed in Column 5 of Table II of this Form 4, and (ii) one non-transferable contingent value right for each share subject to this option, which represents the contractual right to receive up to an additional $2.00 per share upon achievement of a milestone. F13: The shares subject to this option shall fully vest and become exercisable on the date of the 2019 Annual Meeting of the Stockholders of the Issuer, so long as the Reporting Person provides continuous service to the Issuer through such date. The shares subject to this option are fully vested as of the date hereof.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.01 · Expires 2029-05-22	Direct	Reported balance After 2019-10-22 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2019-10-22 · Disposition to issuer · Disposed 22,500 · Balance 0 F3: On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Lundbeck, Lundbeck LLC and Purchaser. On October 22, 2019 (the "Effective Time"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck. F5: The shares subject to this option, whether or not vested, were cancelled and converted into the right to receive both (i) a cash payment equal to (A) the excess, if any of (x) $18.00 over (y) the Exercise Price per share listed in Column 2 of Table II of this Form 4, multiplied by (B) the total number of shares listed in Column 5 of Table II of this Form 4, and (ii) one non-transferable contingent value right for each share subject to this option, which represents the contractual right to receive up to an additional $2.00 per share upon achievement of a milestone. F14: The shares subject to this option shall fully vest and become exercisable on the date of the 2020 Annual Meeting of the Stockholders of the Issuer, so long as the Reporting Person provides continuous service to the Issuer through such date.

Filing footnotes · ownership attribution and instrument terms

F1: On September 16, 2019, the Reporting Person entered into a Tender and Support (the "Support Agreement") with H. Lundbeck A/S ("Lundbeck"), Lundbeck LLC, Violet Acquisition Corp., a wholly owned subsidiary of Lundbeck ("Purchaser") and certain other securityholders of Issuer, pursuant to which the Reporting Person agreed to tender all shares of the Issuer's Common Stock, Class A-1 Convertible Preferred Stock or shares of Common Stock underlying stock options, as the case may be, held by Reporting Person to Purchaser (the "Tender Offer"). On October 22, 2019, Purchaser accepted the Tender Offer.

F2: The Reporting Person will also receive one non-transferable contingent value right for each share held, which will entitle them to receive up to an additional $2.00 per share upon achievement of a milestone.

F3: On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Lundbeck, Lundbeck LLC and Purchaser. On October 22, 2019 (the "Effective Time"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck.

F4: The shares subject to this option shall vest at a rate of twenty-five percent of the total number of shares on the one-year anniversary of October 25, 2010 (the "2010 Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the 2010 Vesting Commencement Date thereafter for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the 2010 Vesting Commencement Date. The shares subject to this option are fully vested as of the date hereof.

F5: The shares subject to this option, whether or not vested, were cancelled and converted into the right to receive both (i) a cash payment equal to (A) the excess, if any of (x) $18.00 over (y) the Exercise Price per share listed in Column 2 of Table II of this Form 4, multiplied by (B) the total number of shares listed in Column 5 of Table II of this Form 4, and (ii) one non-transferable contingent value right for each share subject to this option, which represents the contractual right to receive up to an additional $2.00 per share upon achievement of a milestone.

F6: The shares subject to this option shall vest at a rate of twenty-five percent of the total number of shares on the one-year anniversary of January 1, 2012 (the "2012 Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the 2012 Vesting Commencement Date thereafter for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the 2012 Vesting Commencement Date. The shares subject to this option are fully vested as of the date hereof.

F7: The shares subject to this option shall vest at a rate of twenty-five percent of the total number of shares on the one-year anniversary of January 1, 2013 (the "2013 Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the 2013 Vesting Commencement Date thereafter for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the 2013 Vesting Commencement Date. The shares subject to this option are fully vested as of the date hereof.

F8: The shares subject to this option shall vest at a rate of twenty-five percent of the total number of shares on the one-year anniversary of January 1, 2014 (the "2014 Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the 2014 Vesting Commencement Date thereafter for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the 2014 Vesting Commencement Date. The shares subject to this option are fully vested as of the date hereof.

F9: The shares subject to this option shall fully vest and become exercisable on the date of the 2016 Annual Meeting of the Stockholders of the Issuer, so long as the Reporting Person provides continuous service to the Issuer through such date. The shares subject to this option are fully vested as of the date hereof.

F10: The shares subject to this option, whether vested or not, were cancelled at the Effective Time without any consideration payable therefor.

F11: The shares subject to this option shall fully vest and become exercisable on the date of the 2017 Annual Meeting of the Stockholders of the Issuer, so long as the Reporting Person provides continuous service to the Issuer through such date. The shares subject to this option are fully vested as of the date hereof.

F12: The shares subject to this option shall fully vest and become exercisable on the date of the 2018 Annual Meeting of the Stockholders of the Issuer, so long as the Reporting Person provides continuous service to the Issuer through such date. The shares subject to this option are fully vested as of the date hereof.

F13: The shares subject to this option shall fully vest and become exercisable on the date of the 2019 Annual Meeting of the Stockholders of the Issuer, so long as the Reporting Person provides continuous service to the Issuer through such date. The shares subject to this option are fully vested as of the date hereof.

F14: The shares subject to this option shall fully vest and become exercisable on the date of the 2020 Annual Meeting of the Stockholders of the Issuer, so long as the Reporting Person provides continuous service to the Issuer through such date.

CytoDyn Inc.

Report date July 12, 2018 · Filed November 16, 2018

Section 16 reporting ended · disclosed 2018-11-16. Current position is not established by this disclosure.

No balance rows disclosed in this filing.

GILEAD SCIENCES, INC.

Report date May 08, 2007 · Filed May 15, 2007

Section 16 reporting ended · disclosed 2007-05-15. Current position is not established by this disclosure.

No balance rows disclosed in this filing.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
June 16, 2026 Filed Jul 8, 2026 22:53 UTC	Xencor Inc XNCR · Entity 4487	GrantStock Option (Right to Buy) · Derivative	20,604	$0.00 Strike: $12.20	$0.00	Disclosure SEC source: 0001313936-26-000004 · wk-form4_1783551235.xml · derivative · entry 2 Montgomery Alan Bruce · CIK 0001313936 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,604 Underlying: Common Stock · 20,604 shares Expires 2036-06-15 F2 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over one year beginning on the one-month anniversary of June 16, 2026, such that the total number of shares will be fully vested on June 16, 2027. Read SEC document
June 16, 2026 Filed Jul 8, 2026 22:53 UTC	Xencor Inc XNCR · Entity 4487	GrantCommon Stock	10,302	$0.00	$0.00	Disclosure SEC source: 0001313936-26-000004 · wk-form4_1783551235.xml · nonDerivative · entry 1 Montgomery Alan Bruce · CIK 0001313936 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,849 F1 · shares: Represents restricted stock units that shall fully vest on the first anniversary of the date of grant. Read SEC document
June 15, 2026 Filed Jun 17, 2026 20:01 UTC	Xencor Inc XNCR · Entity 4487	SaleCommon Stock	5,064	$12.31	$62,337.84	Disclosure SEC source: 0001313936-26-000002 · wk-form4_1781726467.xml · nonDerivative · entry 1 Montgomery Alan Bruce · CIK 0001313936 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,547 F1 · kind: This transaction is pursuant to a 10b5-1 plan adopted by the Reporting Person on March 4, 2026. Read SEC document
June 16, 2025 Filed Jun 16, 2025 23:35 UTC	Xencor Inc XNCR · Entity 4487	SaleCommon Stock	2,215	$9.22	$20,422.30	Disclosure SEC source: 0001127602-25-017604 · form4.xml · nonDerivative · entry 2 Montgomery Alan Bruce · CIK 0001313936 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,611 F2 · kind: This transaction is pursuant to a 10b5-1 plan adopted by the Reporting Person on June 28, 2024. Read SEC document
June 12, 2025 Filed Jun 16, 2025 23:35 UTC	Xencor Inc XNCR · Entity 4487	GrantStock Option (Right to Buy) · Derivative	27,372	$0.00 Strike: $9.43	$0.00	Disclosure SEC source: 0001127602-25-017604 · form4.xml · derivative · entry 3 Montgomery Alan Bruce · CIK 0001313936 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,372 Underlying: Common Stock · 27,372 shares Expires 2035-06-11 F3 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over one year beginning on the one-month anniversary of June 12, 2025, such that the total number of shares will be fully vested on June 12, 2026. Read SEC document
June 12, 2025 Filed Jun 16, 2025 23:35 UTC	Xencor Inc XNCR · Entity 4487	GrantCommon Stock	13,686	$0.00	$0.00	Disclosure SEC source: 0001127602-25-017604 · form4.xml · nonDerivative · entry 1 Montgomery Alan Bruce · CIK 0001313936 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,826 F1 · shares: Represents restricted stock units that shall fully vest on the first anniversary of the date of grant. Read SEC document
December 04, 2024 Filed Dec 4, 2024 23:08 UTC	Xencor Inc XNCR · Entity 4487	Exercise / conversionStock Option (Right to Buy) · Derivative	430	$0.00 Strike: $20.00	$0.00	Disclosure SEC source: 0001127602-24-028676 · form4.xml · derivative · entry 10 Montgomery Alan Bruce · CIK 0001313936 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,062 Underlying: Common Stock · 430 shares Expires 2025-06-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction is pursuant to a 10b5-1 plan adopted by the Reporting Person on June 28, 2024. Read SEC document
December 04, 2024 Filed Dec 4, 2024 23:08 UTC	Xencor Inc XNCR · Entity 4487	Exercise / conversionStock Option (Right to Buy) · Derivative	991	$0.00 Strike: $15.35	$0.00	Disclosure SEC source: 0001127602-24-028676 · form4.xml · derivative · entry 9 Montgomery Alan Bruce · CIK 0001313936 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,716 Underlying: Common Stock · 991 shares Expires 2025-03-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction is pursuant to a 10b5-1 plan adopted by the Reporting Person on June 28, 2024. F4 · derivative.exercise_date: 1/3 of the shares subject to the stock option vested and became exercisable on March 18, 2016, and the remaining shares vested in equal monthly installments over the subsequent 24 months. Read SEC document
December 04, 2024 Filed Dec 4, 2024 23:08 UTC	Xencor Inc XNCR · Entity 4487	SaleCommon Stock	1,421	$27.03	$38,406.22	Disclosure SEC source: 0001127602-24-028676 · form4.xml · nonDerivative · entry 6 Montgomery Alan Bruce · CIK 0001313936 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,140 F1 · kind: This transaction is pursuant to a 10b5-1 plan adopted by the Reporting Person on June 28, 2024. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.00 to $27.13, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document
December 04, 2024 Filed Dec 4, 2024 23:08 UTC	Xencor Inc XNCR · Entity 4487	Exercise / conversionCommon Stock	430	$20.00	$8,600.00	Disclosure SEC source: 0001127602-24-028676 · form4.xml · nonDerivative · entry 5 Montgomery Alan Bruce · CIK 0001313936 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,561 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction is pursuant to a 10b5-1 plan adopted by the Reporting Person on June 28, 2024. Read SEC document
December 04, 2024 Filed Dec 4, 2024 23:08 UTC	Xencor Inc XNCR · Entity 4487	Exercise / conversionCommon Stock	991	$15.35	$15,211.85	Disclosure SEC source: 0001127602-24-028676 · form4.xml · nonDerivative · entry 4 Montgomery Alan Bruce · CIK 0001313936 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,131 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction is pursuant to a 10b5-1 plan adopted by the Reporting Person on June 28, 2024. Read SEC document
December 02, 2024 Filed Dec 4, 2024 23:08 UTC	Xencor Inc XNCR · Entity 4487	Exercise / conversionStock Option (Right to Buy) · Derivative	8,293	$0.00 Strike: $15.35	$0.00	Disclosure SEC source: 0001127602-24-028676 · form4.xml · derivative · entry 8 Montgomery Alan Bruce · CIK 0001313936 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 6,707 Underlying: Common Stock · 8,293 shares Expires 2025-03-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction is pursuant to a 10b5-1 plan adopted by the Reporting Person on June 28, 2024. F4 · derivative.exercise_date: 1/3 of the shares subject to the stock option vested and became exercisable on March 18, 2016, and the remaining shares vested in equal monthly installments over the subsequent 24 months. Read SEC document
December 02, 2024 Filed Dec 4, 2024 23:08 UTC	Xencor Inc XNCR · Entity 4487	Exercise / conversionStock Option (Right to Buy) · Derivative	5,008	$0.00 Strike: $20.00	$0.00	Disclosure SEC source: 0001127602-24-028676 · form4.xml · derivative · entry 7 Montgomery Alan Bruce · CIK 0001313936 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,492 Underlying: Common Stock · 5,008 shares Expires 2025-06-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction is pursuant to a 10b5-1 plan adopted by the Reporting Person on June 28, 2024. Read SEC document
December 02, 2024 Filed Dec 4, 2024 23:08 UTC	Xencor Inc XNCR · Entity 4487	SaleCommon Stock	13,301	$27.03	$359,524.70	Disclosure SEC source: 0001127602-24-028676 · form4.xml · nonDerivative · entry 3 Montgomery Alan Bruce · CIK 0001313936 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,140 F1 · kind: This transaction is pursuant to a 10b5-1 plan adopted by the Reporting Person on June 28, 2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.00 to $27.20, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document
December 02, 2024 Filed Dec 4, 2024 23:08 UTC	Xencor Inc XNCR · Entity 4487	Exercise / conversionCommon Stock	5,008	$20.00	$100,160.00	Disclosure SEC source: 0001127602-24-028676 · form4.xml · nonDerivative · entry 2 Montgomery Alan Bruce · CIK 0001313936 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,441 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction is pursuant to a 10b5-1 plan adopted by the Reporting Person on June 28, 2024. Read SEC document
December 02, 2024 Filed Dec 4, 2024 23:08 UTC	Xencor Inc XNCR · Entity 4487	Exercise / conversionCommon Stock	8,293	$15.35	$127,297.55	Disclosure SEC source: 0001127602-24-028676 · form4.xml · nonDerivative · entry 1 Montgomery Alan Bruce · CIK 0001313936 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,433 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction is pursuant to a 10b5-1 plan adopted by the Reporting Person on June 28, 2024. Read SEC document
September 27, 2024 Filed Oct 1, 2024 20:08 UTC	Xencor Inc XNCR · Entity 4487	SaleCommon Stock	1,853	$20.68	$38,320.04	Disclosure SEC source: 0001127602-24-024667 · form4.xml · nonDerivative · entry 1 Montgomery Alan Bruce · CIK 0001313936 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,140 F1 · shares: Sale was pursuant to a 10b5-1 plan arranged to cover withholding taxes upon vesting of restricted stock units. Read SEC document
June 13, 2024 Filed Jun 17, 2024 20:19 UTC	Xencor Inc XNCR · Entity 4487	GrantStock Option (Right to Buy) · Derivative	11,971	$0.00 Strike: $21.31	$0.00	Disclosure SEC source: 0001127602-24-018825 · form4.xml · derivative · entry 2 Montgomery Alan Bruce · CIK 0001313936 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,971 Underlying: Common Stock · 11,971 shares Expires 2034-06-12 F2 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over one year beginning on the one-month anniversary of June 13, 2024, such that the total number of shares will be fully vested on June 13, 2025. Read SEC document
June 13, 2024 Filed Jun 17, 2024 20:19 UTC	Xencor Inc XNCR · Entity 4487	GrantCommon Stock	5,986	$0.00	$0.00	Disclosure SEC source: 0001127602-24-018825 · form4.xml · nonDerivative · entry 1 Montgomery Alan Bruce · CIK 0001313936 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,993 F1 · shares: Represents restricted stock units that shall fully vest on the first anniversary of the date of grant. Read SEC document
June 20, 2023 Filed Jun 22, 2023 21:51 UTC	Xencor Inc XNCR · Entity 4487	GrantStock Option (Right to Buy) · Derivative	10,013	$0.00 Strike: $26.19	$0.00	Disclosure SEC source: 0001127602-23-019284 · form4.xml · derivative · entry 2 Montgomery Alan Bruce · CIK 0001313936 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,013 Underlying: Common Stock · 10,013 shares Expires 2033-06-20 F2 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over one year beginning on the one-month anniversary of June 20, 2023, such that the total number of shares will be fully vested on June 20, 2024. Read SEC document
June 20, 2023 Filed Jun 22, 2023 21:51 UTC	Xencor Inc XNCR · Entity 4487	GrantCommon Stock	5,007	$0.00	$0.00	Disclosure SEC source: 0001127602-23-019284 · form4.xml · nonDerivative · entry 1 Montgomery Alan Bruce · CIK 0001313936 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,007 F1 · shares: Represents restricted stock units that shall fully vest on the first anniversary of the date of grant. Read SEC document
June 23, 2022 Filed Jun 27, 2022 20:35 UTC	Xencor Inc XNCR · Entity 4487	GrantStock Option (Right to Buy) · Derivative	21,412	$0.00 Strike: $26.58	$0.00	Disclosure SEC source: 0001127602-22-018158 · form4.xml · derivative · entry 1 Montgomery Alan Bruce · CIK 0001313936 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,412 Underlying: Common Stock · 21,412 shares Expires 2032-06-23 F1 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over one year beginning on the one-month anniversary of June 23, 2022, such that the total number of shares will be fully vested on June 23, 2023. Read SEC document
June 24, 2021 Filed Jun 26, 2021 00:01 UTC	Xencor Inc XNCR · Entity 4487	GrantStock Option (Right to Buy) · Derivative	9,728	$0.00 Strike: $36.01	$0.00	Disclosure SEC source: 0001415889-21-003235 · form4-06252021_080639.xml · derivative · entry 1 Montgomery Alan Bruce · CIK 0001313936 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,728 Underlying: Common Stock · 9,728 shares Expires 2031-06-24 F1 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over one year beginning on the one-month anniversary of June 24, 2021, such that the total number of shares will be fully vested on June 24, 2022. Read SEC document
June 25, 2020 Filed Jun 30, 2020 00:27 UTC	Xencor Inc XNCR · Entity 4487	GrantStock Option (Right to Buy) · Derivative	13,953	$0.00 Strike: $33.42	$0.00	Disclosure SEC source: 0001209191-20-039290 · doc4.xml · derivative · entry 1 Montgomery Alan Bruce · CIK 0001313936 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,953 Underlying: Common Stock · 13,953 shares Expires 2030-06-24 F1 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over one year beginning on the one-month anniversary of June 25, 2020, such that the total number of shares will be fully vested on June 25, 2021. Read SEC document
October 22, 2019 Filed Oct 24, 2019 18:58 UTC	ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258	Disposition to issuerStock Option (Right to Buy) · Derivative	22,500	$0.00 Strike: $11.01	$0.00	Disclosure SEC source: 0001209191-19-053913 · doc4.xml · derivative · entry 10 Montgomery Alan Bruce · CIK 0001313936 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,500 shares Expires 2029-05-22 F3 · date: On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Lundbeck, Lundbeck LLC and Purchaser. On October 22, 2019 (the "Effective Time"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck. F5 · derivative.exercise_date: The shares subject to this option, whether or not vested, were cancelled and converted into the right to receive both (i) a cash payment equal to (A) the excess, if any of (x) $18.00 over (y) the Exercise Price per share listed in Column 2 of Table II of this Form 4, multiplied by (B) the total number of shares listed in Column 5 of Table II of this Form 4, and (ii) one non-transferable contingent value right for each share subject to this option, which represents the contractual right to receive up to an additional $2.00 per share upon achievement of a milestone. F14 · derivative.exercise_date: The shares subject to this option shall fully vest and become exercisable on the date of the 2020 Annual Meeting of the Stockholders of the Issuer, so long as the Reporting Person provides continuous service to the Issuer through such date. Read SEC document
October 22, 2019 Filed Oct 24, 2019 18:58 UTC	ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258	Disposition to issuerStock Option (Right to Buy) · Derivative	15,000	$0.00 Strike: $15.50	$0.00	Disclosure SEC source: 0001209191-19-053913 · doc4.xml · derivative · entry 9 Montgomery Alan Bruce · CIK 0001313936 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2028-05-22 F3 · date: On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Lundbeck, Lundbeck LLC and Purchaser. On October 22, 2019 (the "Effective Time"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck. F5 · derivative.exercise_date: The shares subject to this option, whether or not vested, were cancelled and converted into the right to receive both (i) a cash payment equal to (A) the excess, if any of (x) $18.00 over (y) the Exercise Price per share listed in Column 2 of Table II of this Form 4, multiplied by (B) the total number of shares listed in Column 5 of Table II of this Form 4, and (ii) one non-transferable contingent value right for each share subject to this option, which represents the contractual right to receive up to an additional $2.00 per share upon achievement of a milestone. F13 · derivative.exercise_date: The shares subject to this option shall fully vest and become exercisable on the date of the 2019 Annual Meeting of the Stockholders of the Issuer, so long as the Reporting Person provides continuous service to the Issuer through such date. The shares subject to this option are fully vested as of the date hereof. Read SEC document
October 22, 2019 Filed Oct 24, 2019 18:58 UTC	ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258	Disposition to issuerStock Option (Right to Buy) · Derivative	15,000	$0.00 Strike: $16.90	$0.00	Disclosure SEC source: 0001209191-19-053913 · doc4.xml · derivative · entry 8 Montgomery Alan Bruce · CIK 0001313936 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2027-05-23 F3 · date: On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Lundbeck, Lundbeck LLC and Purchaser. On October 22, 2019 (the "Effective Time"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck. F5 · derivative.exercise_date: The shares subject to this option, whether or not vested, were cancelled and converted into the right to receive both (i) a cash payment equal to (A) the excess, if any of (x) $18.00 over (y) the Exercise Price per share listed in Column 2 of Table II of this Form 4, multiplied by (B) the total number of shares listed in Column 5 of Table II of this Form 4, and (ii) one non-transferable contingent value right for each share subject to this option, which represents the contractual right to receive up to an additional $2.00 per share upon achievement of a milestone. F12 · derivative.exercise_date: The shares subject to this option shall fully vest and become exercisable on the date of the 2018 Annual Meeting of the Stockholders of the Issuer, so long as the Reporting Person provides continuous service to the Issuer through such date. The shares subject to this option are fully vested as of the date hereof. Read SEC document
October 22, 2019 Filed Oct 24, 2019 18:58 UTC	ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258	Disposition to issuerStock Option (Right to Buy) · Derivative	15,000	$0.00 Strike: $29.26	$0.00	Disclosure SEC source: 0001209191-19-053913 · doc4.xml · derivative · entry 7 Montgomery Alan Bruce · CIK 0001313936 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2026-05-25 F3 · date: On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Lundbeck, Lundbeck LLC and Purchaser. On October 22, 2019 (the "Effective Time"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck. F10 · derivative.exercise_date: The shares subject to this option, whether vested or not, were cancelled at the Effective Time without any consideration payable therefor. F11 · derivative.exercise_date: The shares subject to this option shall fully vest and become exercisable on the date of the 2017 Annual Meeting of the Stockholders of the Issuer, so long as the Reporting Person provides continuous service to the Issuer through such date. The shares subject to this option are fully vested as of the date hereof. Read SEC document
October 22, 2019 Filed Oct 24, 2019 18:58 UTC	ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258	Disposition to issuerStock Option (Right to Buy) · Derivative	6,350	$0.00 Strike: $39.66	$0.00	Disclosure SEC source: 0001209191-19-053913 · doc4.xml · derivative · entry 6 Montgomery Alan Bruce · CIK 0001313936 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,350 shares Expires 2025-05-18 F3 · date: On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Lundbeck, Lundbeck LLC and Purchaser. On October 22, 2019 (the "Effective Time"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck. F9 · derivative.exercise_date: The shares subject to this option shall fully vest and become exercisable on the date of the 2016 Annual Meeting of the Stockholders of the Issuer, so long as the Reporting Person provides continuous service to the Issuer through such date. The shares subject to this option are fully vested as of the date hereof. F10 · derivative.exercise_date: The shares subject to this option, whether vested or not, were cancelled at the Effective Time without any consideration payable therefor. Read SEC document
October 22, 2019 Filed Oct 24, 2019 18:58 UTC	ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258	Disposition to issuerStock Option (Right to Buy) · Derivative	6,363	$0.00 Strike: $6.33	$0.00	Disclosure SEC source: 0001209191-19-053913 · doc4.xml · derivative · entry 5 Montgomery Alan Bruce · CIK 0001313936 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,363 shares Expires 2024-01-08 F3 · date: On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Lundbeck, Lundbeck LLC and Purchaser. On October 22, 2019 (the "Effective Time"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck. F5 · derivative.exercise_date: The shares subject to this option, whether or not vested, were cancelled and converted into the right to receive both (i) a cash payment equal to (A) the excess, if any of (x) $18.00 over (y) the Exercise Price per share listed in Column 2 of Table II of this Form 4, multiplied by (B) the total number of shares listed in Column 5 of Table II of this Form 4, and (ii) one non-transferable contingent value right for each share subject to this option, which represents the contractual right to receive up to an additional $2.00 per share upon achievement of a milestone. F8 · derivative.exercise_date: The shares subject to this option shall vest at a rate of twenty-five percent of the total number of shares on the one-year anniversary of January 1, 2014 (the "2014 Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the 2014 Vesting Commencement Date thereafter for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the 2014 Vesting Commencement Date. The shares subject to this option are fully vested as of the date hereof. Read SEC document
October 22, 2019 Filed Oct 24, 2019 18:58 UTC	ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258	Disposition to issuerStock Option (Right to Buy) · Derivative	6,363	$0.00 Strike: $3.47	$0.00	Disclosure SEC source: 0001209191-19-053913 · doc4.xml · derivative · entry 4 Montgomery Alan Bruce · CIK 0001313936 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,363 shares Expires 2023-03-12 F3 · date: On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Lundbeck, Lundbeck LLC and Purchaser. On October 22, 2019 (the "Effective Time"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck. F5 · derivative.exercise_date: The shares subject to this option, whether or not vested, were cancelled and converted into the right to receive both (i) a cash payment equal to (A) the excess, if any of (x) $18.00 over (y) the Exercise Price per share listed in Column 2 of Table II of this Form 4, multiplied by (B) the total number of shares listed in Column 5 of Table II of this Form 4, and (ii) one non-transferable contingent value right for each share subject to this option, which represents the contractual right to receive up to an additional $2.00 per share upon achievement of a milestone. F7 · derivative.exercise_date: The shares subject to this option shall vest at a rate of twenty-five percent of the total number of shares on the one-year anniversary of January 1, 2013 (the "2013 Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the 2013 Vesting Commencement Date thereafter for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the 2013 Vesting Commencement Date. The shares subject to this option are fully vested as of the date hereof. Read SEC document
October 22, 2019 Filed Oct 24, 2019 18:58 UTC	ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258	Disposition to issuerStock Option (Right to Buy) · Derivative	6,363	$0.00 Strike: $3.47	$0.00	Disclosure SEC source: 0001209191-19-053913 · doc4.xml · derivative · entry 3 Montgomery Alan Bruce · CIK 0001313936 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,363 shares Expires 2023-03-12 F3 · date: On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Lundbeck, Lundbeck LLC and Purchaser. On October 22, 2019 (the "Effective Time"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck. F5 · derivative.exercise_date: The shares subject to this option, whether or not vested, were cancelled and converted into the right to receive both (i) a cash payment equal to (A) the excess, if any of (x) $18.00 over (y) the Exercise Price per share listed in Column 2 of Table II of this Form 4, multiplied by (B) the total number of shares listed in Column 5 of Table II of this Form 4, and (ii) one non-transferable contingent value right for each share subject to this option, which represents the contractual right to receive up to an additional $2.00 per share upon achievement of a milestone. F6 · derivative.exercise_date: The shares subject to this option shall vest at a rate of twenty-five percent of the total number of shares on the one-year anniversary of January 1, 2012 (the "2012 Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the 2012 Vesting Commencement Date thereafter for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the 2012 Vesting Commencement Date. The shares subject to this option are fully vested as of the date hereof. Read SEC document
October 22, 2019 Filed Oct 24, 2019 18:58 UTC	ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258	Disposition to issuerStock Option (Right to Buy) · Derivative	12,727	$0.00 Strike: $3.96	$0.00	Disclosure SEC source: 0001209191-19-053913 · doc4.xml · derivative · entry 2 Montgomery Alan Bruce · CIK 0001313936 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,727 shares Expires 2021-05-09 F3 · date: On September 16, 2019, the Issuer entered into an Agreement and Plan of Merger (the "Merger Agreement") with Lundbeck, Lundbeck LLC and Purchaser. On October 22, 2019 (the "Effective Time"), Purchaser merged with and into the Issuer pursuant to Section 251(h) of the General Corporation Law of the State of Delaware, with the Issuer being the surviving corporation and becoming a wholly-owned subsidiary of Lundbeck. F4 · derivative.exercise_date: The shares subject to this option shall vest at a rate of twenty-five percent of the total number of shares on the one-year anniversary of October 25, 2010 (the "2010 Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the 2010 Vesting Commencement Date thereafter for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the 2010 Vesting Commencement Date. The shares subject to this option are fully vested as of the date hereof. F5 · derivative.exercise_date: The shares subject to this option, whether or not vested, were cancelled and converted into the right to receive both (i) a cash payment equal to (A) the excess, if any of (x) $18.00 over (y) the Exercise Price per share listed in Column 2 of Table II of this Form 4, multiplied by (B) the total number of shares listed in Column 5 of Table II of this Form 4, and (ii) one non-transferable contingent value right for each share subject to this option, which represents the contractual right to receive up to an additional $2.00 per share upon achievement of a milestone. Read SEC document
October 22, 2019 Filed Oct 24, 2019 18:58 UTC	ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258	OtherCommon Stock	9,628	$18.00	$173,304.00	Disclosure SEC source: 0001209191-19-053913 · doc4.xml · nonDerivative · entry 1 Montgomery Alan Bruce · CIK 0001313936 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · date: On September 16, 2019, the Reporting Person entered into a Tender and Support (the "Support Agreement") with H. Lundbeck A/S ("Lundbeck"), Lundbeck LLC, Violet Acquisition Corp., a wholly owned subsidiary of Lundbeck ("Purchaser") and certain other securityholders of Issuer, pursuant to which the Reporting Person agreed to tender all shares of the Issuer's Common Stock, Class A-1 Convertible Preferred Stock or shares of Common Stock underlying stock options, as the case may be, held by Reporting Person to Purchaser (the "Tender Offer"). On October 22, 2019, Purchaser accepted the Tender Offer. F2 · price: The Reporting Person will also receive one non-transferable contingent value right for each share held, which will entitle them to receive up to an additional $2.00 per share upon achievement of a milestone. Read SEC document
June 26, 2019 Filed Jun 27, 2019 23:41 UTC	Xencor Inc XNCR · Entity 4487	GrantStock Option (Right to Buy) · Derivative	12,731	$0.00 Strike: $39.08	$0.00	Disclosure SEC source: 0001209191-19-039380 · doc4.xml · derivative · entry 1 Montgomery Alan Bruce · CIK 0001313936 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,731 Underlying: Common Stock · 12,731 shares Expires 2029-06-25 F1 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over one year beginning on the one-month anniversary of June 26, 2019, such that the total number of shares will be fully vested on June 26, 2020. Read SEC document
May 23, 2019 Filed May 28, 2019 18:14 UTC	ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258	GrantStock Option (Right to Buy) · Derivative	22,500	$0.00 Strike: $11.01	$0.00	Disclosure SEC source: 0001209191-19-033074 · doc4.xml · derivative · entry 1 Montgomery Alan Bruce · CIK 0001313936 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2029-05-22 F1 · derivative.exercise_date: The shares subject to this option shall fully vest and become exercisable on the date of the 2020 Annual Meeting of the Stockholders of the Issuer, so long as the Reporting Person provides continuous service to the Issuer through such date. Read SEC document
June 26, 2018 Filed Jun 27, 2018 21:59 UTC	Xencor Inc XNCR · Entity 4487	GrantStock Option (Right to Buy) · Derivative	7,500	$0.00 Strike: $38.93	$0.00	Disclosure SEC source: 0001209191-18-039697 · doc4.xml · derivative · entry 1 Montgomery Alan Bruce · CIK 0001313936 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2028-06-25 F1 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over one year beginning on the one-month anniversary of June 26, 2018, such that the total number of shares will be fully vested on June 26, 2019. Read SEC document
June 08, 2018 Filed Jun 12, 2018 21:58 UTC	CytoDyn Inc. CYDY · Entity 5856	GrantStock Options (right to buy) · Derivative	100,000	$0.00 Strike: $0.49	$0.00	Disclosure SEC source: 0000899243-18-016234 · doc4.xml · derivative · entry 1 Montgomery Alan Bruce · CIK 0001313936 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2028-06-08 F1 · derivative.exercise_date: The options will vest in four equal quarterly installments commencing on September 1, 2018. Read SEC document
May 23, 2018 Filed May 25, 2018 17:14 UTC	ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258	GrantStock Option (Right to Buy) · Derivative	15,000	$0.00 Strike: $15.50	$0.00	Disclosure SEC source: 0001209191-18-033581 · doc4.xml · derivative · entry 1 Montgomery Alan Bruce · CIK 0001313936 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2028-05-22 F1 · derivative.exercise_date: The shares subject to this option shall fully vest and become exercisable on the date of the 2019 Annual Meeting of the Stockholders of the Issuer, so long as the Reporting Person provides continuous service to the Issuer through such date. Read SEC document
February 07, 2018 Filed Feb 10, 2018 01:06 UTC	CytoDyn Inc. CYDY · Entity 5856	GrantStock Options (right to buy) · Derivative	136,563	Not disclosed Strike: $0.56	Not disclosed	Disclosure SEC source: 0000899243-18-003459 · doc4.xml · derivative · entry 1 Montgomery Alan Bruce · CIK 0001313936 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 136,563 Underlying: Common Stock · 136,563 shares Expires 2028-02-07 F1 · price: On February 7, 2018, the board of directors of CytoDyn Inc. approved an amendment to its director compensation program, providing for payment in stock options, in lieu of cash, of all unpaid director retainer fees for the four-quarter period ending February 28, 2018. The number of options awarded to each director was determined by applying a price of $0.31 per option, which was the fair value estimate of the option award as of the grant date, using the Black-Scholes option pricing model Read SEC document
June 22, 2017 Filed Jun 26, 2017 20:32 UTC	Xencor Inc XNCR · Entity 4487	GrantStock Option (Right to Buy) · Derivative	7,500	$0.00 Strike: $22.20	$0.00	Disclosure SEC source: 0001209191-17-041839 · doc4.xml · derivative · entry 1 Montgomery Alan Bruce · CIK 0001313936 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2027-06-21 F1 · derivative.exercise_date: The shares subject to the option will vest in equal monthly installments over one year beginning on the one-month anniversary of June 22, 2017, such that the total number of shares will be fully vested on June 22, 2018. Read SEC document
June 01, 2017 Filed Jun 5, 2017 20:45 UTC	CytoDyn Inc. CYDY · Entity 5856	GrantStock Options (right to buy) · Derivative	75,000	$0.00 Strike: $0.57	$0.00	Disclosure SEC source: 0000899243-17-015352 · doc4.xml · derivative · entry 1 Montgomery Alan Bruce · CIK 0001313936 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2027-06-01 F1 · derivative.exercise_date: Subject to stockholder approval, at the next annual meeting, of the increase in the number of shares of common stock authorized for issuance under the CytoDyn Inc. 2012 Equity Incentive Plan, as amended, the options will vest in four equal quarterly installments commencing on September 1, 2017. Read SEC document
May 24, 2017 Filed May 26, 2017 18:15 UTC	ALDER BIOPHARMACEUTICALS INC ALDR · Entity 154258	GrantStock Option (Right to Buy) · Derivative	15,000	$0.00 Strike: $16.90	$0.00	Disclosure SEC source: 0001209191-17-036008 · doc4.xml · derivative · entry 1 Montgomery Alan Bruce · CIK 0001313936 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2027-05-23 F1 · derivative.exercise_date: The shares subject to this option shall fully vest and become exercisable on the date of the 2018 Annual Meeting of the Stockholders of the Issuer, so long as the Reporting Person provides continuous service to the Issuer through such date. Read SEC document
June 23, 2016 Filed Mar 4, 2021 01:00 UTC Amendment	Xencor Inc XNCR · Entity 4487	GrantStock Options · Derivative	7,500	$0.00 Strike: $14.43	$0.00	Disclosure SEC source: 0001415889-21-001294 · form4a-03032021_080308.xml · derivative · entry 1 Montgomery Alan Bruce · CIK 0001313936 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2026-06-22 F1 · derivative.exercise_price: The initial filing incorrectly listed the exercise price at $14.83 per share due to an administrative error. F2 · derivative.exercise_date: 100% of the shares subject to the option vest on June 23, 2017. Read SEC document
January 22, 2007 Filed Jan 24, 2007 21:47 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	GrantNon-Qualified Stock Option (right to buy) · Derivative	20,000	$0.00 Strike: $65.58	$0.00	Disclosure SEC source: 0001179110-07-001860 · edgar.xml · derivative · entry 1 Montgomery Alan Bruce · CIK 0001313936 · SVP, Respiratory Therapeutics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2017-01-22 F1 · derivative.exercise_date: Options vest over a five year period beginning 1/22/2008, the first anniversary of the grant. The options continue to vest in quarterly installments over the next four years, ending on 1/22/2012. Read SEC document
September 11, 2006 Filed Sep 12, 2006 23:32 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	GrantNon-Qualified Stock Option (right to buy) · Derivative	70,000	$0.00 Strike: $63.69	$0.00	Disclosure SEC source: 0001179110-06-018343 · edgar.xml · derivative · entry 3 Montgomery Alan Bruce · CIK 0001313936 · SVP, Respiratory Therapeutics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2016-09-11 F3 · derivative.exercise_date: Options will vest 20% on September 11, 2007, the first anniversay date of the grant. The balance will vest 5% every three months thereafter until fully vested on September 11, 2011. Read SEC document
September 11, 2006 Filed Sep 12, 2006 23:32 UTC	GILEAD SCIENCES, INC. GILD · Entity 405	GrantCommon Stock	14,000	$0.00	$0.00	Disclosure SEC source: 0001179110-06-018343 · edgar.xml · nonDerivative · entry 1 Montgomery Alan Bruce · CIK 0001313936 · SVP, Respiratory Therapeutics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,280 F1 · shares: The shares are issued as a restricted stock award scheduled to vest in three equal installments contingent upon the achievement of certain pre-determined milestones. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.